 [1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LORAZEPAM increase or decrease the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does LORAZEPAM increase or decrease the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes LORAZEPAM increase or decrease the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LORAZEPAM increase or decrease the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does LORAZEPAM increase or decrease the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"LORAZEPAM"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: LORAZEPAM: adverse_reactions: ADVERSE REACTIONS Most adverse reactions to benzodiazepines, including CNS effects and respiratory depression, are dose dependent, with more severe effects [0m
[31moccurring with high doses. In a sample of about [0m[1;31m3500[0m[31m patients treated for anxiety, the most frequent adverse reaction to lorazepam was sedation [0m[1;31m([0m[1;31m15.9[0m[31m%[0m[1;31m)[0m[31m, followed by dizziness [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m, weakness [0m[1;31m([0m[1;31m4.2[0m[31m%[0m[1;31m)[0m[31m, [0m
[31mand unsteadiness [0m[1;31m([0m[1;31m3.4[0m[31m%[0m[1;31m)[0m[31m. The incidence of sedation and unsteadiness increased with age. LORAZEPAM: adverse_reactions: Other adverse reactions to benzodiazepines, including lorazepam are fatigue, [0m
[31mdrowsiness, amnesia, memory impairment, confusion, disorientation, depression, unmasking of depression, disinhibition, euphoria, suicidal ideation/attempt, ataxia, asthenia, extrapyramidal symptoms, [0m
[31mconvulsions/seizures, tremor, vertigo, eye function/visual disturbance [0m[1;31m([0m[31mincluding diplopia and blurred vision[0m[1;31m)[0m[31m, dysarthria/slurred speech, change in libido, impotence, decreased orgasm; headache, [0m
[31mcoma; respiratory depression, apnea, worsening of sleep apnea, worsening of obstructive pulmonary disease; gastrointestinal symptoms including nausea, change in appetite, constipation, jaundice, [0m
[31mincrease in bilirubin, increase in liver transaminases, increase in alkaline phosphatase; hypersensitivity reactions, anaphylactoid reactions; dermatological symptoms, allergic skin reactions, [0m
[31malopecia; syndrome of inappropriate antidiuretic LORAZEPAM: adverse_reactions: hormone [0m[1;31m([0m[31mSIADH[0m[1;31m)[0m[31m, hyponatremia; thrombocytopenia, agranulocytosis, pancytopenia; hypothermia; and autonomic [0m
[31mmanifestations. Paradoxical reactions, including anxiety, excitation, agitation, hostility, aggression, rage, sleep disturbances/insomnia, sexual arousal, and hallucinations may occur. Small decreases[0m
[31min blood pressure and hypotension may occur but are usually not clinically significant, probably being related to the relief of anxiety produced by lorazepam. To report SUSPECTED ADVERSE REACTIONS, [0m
[31mcontact Aurobindo Pharma USA, Inc. at [0m[1;31m1[0m[31m-[0m[1;31m866[0m[31m-[0m[1;31m850[0m[31m-[0m[1;31m2876[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www.fda.gov/medwatch.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: carcinogenesis_and_mutagenesis_and_impairment_of_fertility: Carcinogenesis and Mutagenesis No evidence of carcinogenic potential emerged in rats during an [0m[1;31m18[0m[31m-month study with [0m
[31mlorazepam. No studies regarding mutagenesis have been performed.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: pregnancy: Although early studies reported an increased risk of congenital malformations with diazepam and chlordiazepoxide, there was no consistent pattern noted. In addition, the[0m
[31mmajority of more recent case-control and cohort studies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco and other medications, have not [0m
[31mconfirmed these findings. Animal Data Reproductive studies in animals were performed in mice, rats, and two strains of rabbits. Occasional anomalies [0m[1;31m([0m[31mreduction of tarsals, tibia, metatarsals, [0m
[31mmalrotated limbs, gastroschisis, malformed skull, and microphthalmia[0m[1;31m)[0m[31m were seen in drug-treated rabbits without relationship to dosage. Although all of these anomalies were not present in the [0m
[31mconcurrent control group, they have been reported to occur randomly in historical controls. At doses of [0m[1;31m40[0m[31m mg/kg and higher, there was evidence of fetal resorption and increased fetal loss in rabbits [0m
[31mwhich was not seen at lower doses. LORAZEPAM: precautions: Nursing Mothers Risk Summary Lorazepam is present in breast milk. There are reports of sedation, poor feeding and poor weight gain in infants[0m
[31mexposed to benzodiazepines through breast milk. The effects of lorazepam on milk production are unknown. The developmental and health benefits of breastfeeding should be considered along with the [0m
[31mmotherâ€™s clinical need for lorazepam and any potential adverse effects on the breastfed infant from lorazepam or from the underlying maternal condition. Clinical Considerations Infants exposed to [0m
[31mlorazepam through breast milk should be monitored for sedation, poor feeding and poor weight gain. Geriatric Use Clinical studies of lorazepam generally were not adequate to determine whether subjects[0m
[31maged [0m[1;31m65[0m[31m and over respond differently than younger subjects; however, the incidence of sedation and unsteadiness was observed to increase with age [0m[1;31m([0m[31msee ADVERSE REACTIONS [0m[1;31m)[0m[31m. Age does not appear to have [0m
[31ma significant effect on lorazepam kinetics [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY [0m[1;31m)[0m[31m. LORAZEPAM: precautions: Clinical circumstances, some of which may be more common in the elderly, such as hepatic or renal [0m
[31mimpairment, should be considered. Greater sensitivity [0m[1;31m([0m[31me.g., sedation[0m[1;31m)[0m[31m of some older individuals cannot be ruled out. In general, dose selection for an elderly patient should be cautious, and lower [0m
[31mdoses may be sufficient in these patients [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: boxed_warning: WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS â€¢ Concomitant use of benzodiazepines and [0m
[31mopioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. [0m
[31mLimit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [0m[1;31m([0m[31msee WARNINGS and PRECAUTIONS [0m[1;31m)[0m[31m. â€¢ The use of benzodiazepines, [0m
[31mincluding lorazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other [0m
[31mmedications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. LORAZEPAM: boxed_warning: Before prescribing lorazepam and throughout [0m
[31mtreatment, assess each patientâ€™s risk for abuse, misuse, and addiction [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. â€¢ The continued use of benzodiazepines, including lorazepam, may lead to clinically significant physical [0m
[31mdependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of lorazepam after continued use may [0m
[31mprecipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam or reduce the dosage [0m[1;31m([0m[31m DOSAGE AND [0m
[31mADMINISTRATION and WARNINGS [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: precautions: Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lorazepam during pregnancy [0m[1;31m([0m[31msee PRECAUTIONS: Pregnancy[0m
[1;31m)[0m[31m. Nursing Instruct patients to notify their healthcare provider if they are breastfeeding or intend to breastfeed. Instruct breastfeeding patients using lorazepam to monitor infants for excessive [0m
[31msedation, poor feeding and poor weight gain, and to seek medical attention if they notice these signs [0m[1;31m([0m[31msee PRECAUTIONS: Nursing Mothers [0m[1;31m)[0m[31m. Essential Laboratory Tests Some patients on lorazepam have [0m
[31mdeveloped leukopenia, and some have had elevations of LDH. As with other benzodiazepines, periodic blood counts and liver function tests are recommended for patients on long-term therapy. Drug [0m
[31mInteractions The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. [0m
[31mBenzodiazepines interact at GABA A sites and opioids interact primarily at mu receptors. LORAZEPAM: precautions: When benzodiazepines and opioids are combined, the potential for benzodiazepines to [0m
[31msignificantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression [0m
[31mand sedation. The benzodiazepines, including lorazepam, produce increased CNS-depressant effects when administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, [0m
[31msedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. Concomitant use of clozapine and lorazepam may produce marked [0m
[31msedation, excessive salivation, hypotension, ataxia, delirium, and respiratory arrest. Concurrent administration of lorazepam with valproate results in increased plasma concentrations and reduced [0m
[31mclearance of lorazepam. LORAZEPAM: precautions: Lorazepam dosage should be reduced to approximately [0m[1;31m50[0m[31m% when coadministered with valproate. Concurrent administration of lorazepam with probenecid may [0m
[31mresult in a more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. Lorazepam dosage needs to be reduced by approximately [0m[1;31m50[0m[31m% when coadministered [0m
[31mwith probenecid. The effects of probenecid and valproate on lorazepam may be due to inhibition of glucuronidation. Administration of theophylline or aminophylline may reduce the sedative effects of [0m
[31mbenzodiazepines, including lorazepam. Carcinogenesis and Mutagenesis No evidence of carcinogenic potential emerged in rats during an [0m[1;31m18[0m[31m-month study with lorazepam. No studies regarding mutagenesis [0m
[31mhave been performed. LORAZEPAM: pregnancy: Pregnancy Pregnancy Exposure Registry There is a pregnancy registry that monitors pregnancy outcomes in women exposed to psychiatric medications, including [0m
[31mlorazepam, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at [0m[1;31m1[0m[31m-[0m[1;31m866[0m[31m-[0m[1;31m961[0m[31m-[0m[1;31m2388[0m[31m or visiting online at [0m
[4;31mhttps://womensmentalhealth.org/pregnancyregistry/.[0m[31m Risk Summary Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal [0m
[31mwithdrawal [0m[1;31m([0m[31msee WARNINGS: Neonatal Sedation and Withdrawal Syndrome and Clinical Considerations [0m[1;31m)[0m[31m. Available data from published observational studies of pregnant women exposed to benzodiazepines do [0m
[31mnot report a clear association with benzodiazepines and major birth defects [0m[1;31m([0m[31msee Data[0m[1;31m)[0m[31m . The background risk of major birth defects and miscarriage for the indicated population is unknown. All [0m
[31mpregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. LORAZEPAM: pregnancy: general population, the estimated risk of major birth defects and of miscarriage [0m
[31min clinically recognized pregnancies is [0m[1;31m2[0m[31m% to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m% to [0m[1;31m20[0m[31m%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Benzodiazepines cross the placenta and may produce respiratory [0m
[31mdepression, hypotonia and sedation in neonates. Monitor neonates exposed to lorazepam during pregnancy or labor for signs of sedation, respiratory depression, hypotonia, and feeding problems. Monitor [0m
[31mneonates exposed to lorazepam during pregnancy for signs of withdrawal. Manage these neonates accordingly [0m[1;31m([0m[31msee WARNINGS: Neonatal Sedation and Withdrawal Syndrome [0m[1;31m)[0m[31m. Data Human Data Published data [0m
[31mfrom observational studies on the use of benzodiazepines during pregnancy do not report a clear association with benzodiazepines and major birth defects.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: openfda: pharm_class_cs         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: drug_interactions: Drug Interactions The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites [0m
[31min the CNS that control respiration. Benzodiazepines interact at GABA A sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for [0m
[31mbenzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for [0m
[31mrespiratory depression and sedation. The benzodiazepines, including lorazepam, produce increased CNS-depressant effects when administered with other CNS depressants such as alcohol, barbiturates, [0m
[31mantipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. LORAZEPAM: drug_interactions: Concomitant use of [0m
[31mclozapine and lorazepam may produce marked sedation, excessive salivation, hypotension, ataxia, delirium, and respiratory arrest. Concurrent administration of lorazepam with valproate results in [0m
[31mincreased plasma concentrations and reduced clearance of lorazepam. Lorazepam dosage should be reduced to approximately [0m[1;31m50[0m[31m% when coadministered with valproate. Concurrent administration of lorazepam [0m
[31mwith probenecid may result in a more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. Lorazepam dosage needs to be reduced by approximately [0m[1;31m50[0m[31m% [0m
[31mwhen coadministered with probenecid. The effects of probenecid and valproate on lorazepam may be due to inhibition of glucuronidation. Administration of theophylline or aminophylline may reduce the [0m
[31msedative effects of benzodiazepines, including lorazepam.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: openfda: spl_id         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: clinical_pharmacology: CLINICAL PHARMACOLOGY Studies in healthy volunteers show that in single high doses lorazepam has a tranquilizing action on the central nervous system with no[0m
[31mappreciable effect on the respiratory or cardiovascular systems. Lorazepam is readily absorbed with an absolute bioavailability of [0m[1;31m90[0m[31m%. Peak concentrations in plasma occur approximately [0m[1;31m2[0m[31m hours [0m
[31mfollowing administration. The peak plasma level of lorazepam from a [0m[1;31m2[0m[31m mg dose is approximately [0m[1;31m20[0m[31m ng/mL. The mean half-life of unconjugated lorazepam in human plasma is about [0m[1;31m12[0m[31m hours and for its [0m
[31mmajor metabolite, lorazepam glucuronide, about [0m[1;31m18[0m[31m hours. At clinically relevant concentrations, lorazepam is approximately [0m[1;31m85[0m[31m% bound to plasma proteins. Lorazepam is rapidly conjugated at its [0m
[1;31m3[0m[31m-hydroxy group into lorazepam glucuronide which is then excreted in the urine. Lorazepam glucuronide has no demonstrable central nervous system [0m[1;31m([0m[31mCNS[0m[1;31m)[0m[31m activity in animals. LORAZEPAM: [0m
[31mclinical_pharmacology: The plasma levels of lorazepam are proportional to the dose given. There is no evidence of accumulation of lorazepam on administration up to [0m[1;31m6[0m[31m months. Studies comparing young [0m
[31mand elderly subjects have shown that advancing age does not have a significant effect on the pharmacokinetics of lorazepam. However, in one study involving single intravenous doses of [0m[1;31m1.5[0m[31m to [0m[1;31m3[0m[31m mg of [0m
[31mlorazepam Injection, mean total body clearance of lorazepam decreased by [0m[1;31m20[0m[31m% in [0m[1;31m15[0m[31m elderly subjects of [0m[1;31m60[0m[31m to [0m[1;31m84[0m[31m years of age compared to that in [0m[1;31m15[0m[31m younger subjects of [0m[1;31m19[0m[31m to [0m[1;31m38[0m[31m years of age.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: dosage_and_administration: DOSAGE AND ADMINISTRATION Lorazepam tablets are administered orally. For optimal results, dose, frequency of administration, and duration of therapy [0m
[31mshould be individualized according to patient response. To facilitate this, [0m[1;31m0.5[0m[31m mg, [0m[1;31m1[0m[31m mg, and [0m[1;31m2[0m[31m mg tablets are available. The usual range is [0m[1;31m2[0m[31m to [0m[1;31m6[0m[31m mg/day given in divided doses, the largest dose [0m
[31mbeing taken before bedtime, but the daily dosage may vary from [0m[1;31m1[0m[31m to [0m[1;31m10[0m[31m mg/day. For anxiety, most patients require an initial dose of [0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m mg/day given two times a day or three times a day. For [0m
[31minsomnia due to anxiety or transient situational stress, a single daily dose of [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m mg may be given, usually at bedtime. For elderly or debilitated patients, an initial dosage of [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m mg/day in [0m
[31mdivided doses is recommended, to be adjusted as needed and tolerated. LORAZEPAM: dosage_and_administration: The dosage of lorazepam tablets should be increased gradually when needed to help avoid [0m
[31madverse effects. When higher dosage is indicated, the evening dose should be increased before the daytime doses. Discontinuation or Dosage Reduction of Lorazepam Tablets To reduce the risk of [0m
[31mwithdrawal reactions, use a gradual taper to discontinue lorazepam tablets or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the [0m
[31mprevious tapered dosage level. Subsequently decrease the dosage more slowly [0m[1;31m([0m[31msee WARNINGS: Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE: Dependence [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:LORAZEPAM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does LORAZEPAM increase or decrease the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"LORAZEPAM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does LORAZEPAM increase or decrease the risk of [0m
[31maplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does LORAZEPAM increase or decrease the risk of aplastic anemia?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes LORAZEPAM increase or decrease the risk of aplastic anemia?[0m
 [1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LORAZEPAM increase or decrease the risk of aplastic anemia?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does LORAZEPAM increase or decrease the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"LORAZEPAM"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: LORAZEPAM: adverse_reactions: ADVERSE REACTIONS Most adverse reactions to benzodiazepines, including CNS effects and respiratory depression, are dose dependent, with more severe effects [0m
[31moccurring with high doses. In a sample of about [0m[1;31m3500[0m[31m patients treated for anxiety, the most frequent adverse reaction to lorazepam was sedation [0m[1;31m([0m[1;31m15.9[0m[31m%[0m[1;31m)[0m[31m, followed by dizziness [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m, weakness [0m[1;31m([0m[1;31m4.2[0m[31m%[0m[1;31m)[0m[31m, [0m
[31mand unsteadiness [0m[1;31m([0m[1;31m3.4[0m[31m%[0m[1;31m)[0m[31m. The incidence of sedation and unsteadiness increased with age. LORAZEPAM: adverse_reactions: Other adverse reactions to benzodiazepines, including lorazepam are fatigue, [0m
[31mdrowsiness, amnesia, memory impairment, confusion, disorientation, depression, unmasking of depression, disinhibition, euphoria, suicidal ideation/attempt, ataxia, asthenia, extrapyramidal symptoms, [0m
[31mconvulsions/seizures, tremor, vertigo, eye function/visual disturbance [0m[1;31m([0m[31mincluding diplopia and blurred vision[0m[1;31m)[0m[31m, dysarthria/slurred speech, change in libido, impotence, decreased orgasm; headache, [0m
[31mcoma; respiratory depression, apnea, worsening of sleep apnea, worsening of obstructive pulmonary disease; gastrointestinal symptoms including nausea, change in appetite, constipation, jaundice, [0m
[31mincrease in bilirubin, increase in liver transaminases, increase in alkaline phosphatase; hypersensitivity reactions, anaphylactoid reactions; dermatological symptoms, allergic skin reactions, [0m
[31malopecia; syndrome of inappropriate antidiuretic LORAZEPAM: adverse_reactions: hormone [0m[1;31m([0m[31mSIADH[0m[1;31m)[0m[31m, hyponatremia; thrombocytopenia, agranulocytosis, pancytopenia; hypothermia; and autonomic [0m
[31mmanifestations. Paradoxical reactions, including anxiety, excitation, agitation, hostility, aggression, rage, sleep disturbances/insomnia, sexual arousal, and hallucinations may occur. Small decreases[0m
[31min blood pressure and hypotension may occur but are usually not clinically significant, probably being related to the relief of anxiety produced by lorazepam. To report SUSPECTED ADVERSE REACTIONS, [0m
[31mcontact Aurobindo Pharma USA, Inc. at [0m[1;31m1[0m[31m-[0m[1;31m866[0m[31m-[0m[1;31m850[0m[31m-[0m[1;31m2876[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www.fda.gov/medwatch.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: carcinogenesis_and_mutagenesis_and_impairment_of_fertility: Carcinogenesis and Mutagenesis No evidence of carcinogenic potential emerged in rats during an [0m[1;31m18[0m[31m-month study with [0m
[31mlorazepam. No studies regarding mutagenesis have been performed.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: pregnancy: Although early studies reported an increased risk of congenital malformations with diazepam and chlordiazepoxide, there was no consistent pattern noted. In addition, the[0m
[31mmajority of more recent case-control and cohort studies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco and other medications, have not [0m
[31mconfirmed these findings. Animal Data Reproductive studies in animals were performed in mice, rats, and two strains of rabbits. Occasional anomalies [0m[1;31m([0m[31mreduction of tarsals, tibia, metatarsals, [0m
[31mmalrotated limbs, gastroschisis, malformed skull, and microphthalmia[0m[1;31m)[0m[31m were seen in drug-treated rabbits without relationship to dosage. Although all of these anomalies were not present in the [0m
[31mconcurrent control group, they have been reported to occur randomly in historical controls. At doses of [0m[1;31m40[0m[31m mg/kg and higher, there was evidence of fetal resorption and increased fetal loss in rabbits [0m
[31mwhich was not seen at lower doses. LORAZEPAM: precautions: Nursing Mothers Risk Summary Lorazepam is present in breast milk. There are reports of sedation, poor feeding and poor weight gain in infants[0m
[31mexposed to benzodiazepines through breast milk. The effects of lorazepam on milk production are unknown. The developmental and health benefits of breastfeeding should be considered along with the [0m
[31mmotherâ€™s clinical need for lorazepam and any potential adverse effects on the breastfed infant from lorazepam or from the underlying maternal condition. Clinical Considerations Infants exposed to [0m
[31mlorazepam through breast milk should be monitored for sedation, poor feeding and poor weight gain. Geriatric Use Clinical studies of lorazepam generally were not adequate to determine whether subjects[0m
[31maged [0m[1;31m65[0m[31m and over respond differently than younger subjects; however, the incidence of sedation and unsteadiness was observed to increase with age [0m[1;31m([0m[31msee ADVERSE REACTIONS [0m[1;31m)[0m[31m. Age does not appear to have [0m
[31ma significant effect on lorazepam kinetics [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY [0m[1;31m)[0m[31m. LORAZEPAM: precautions: Clinical circumstances, some of which may be more common in the elderly, such as hepatic or renal [0m
[31mimpairment, should be considered. Greater sensitivity [0m[1;31m([0m[31me.g., sedation[0m[1;31m)[0m[31m of some older individuals cannot be ruled out. In general, dose selection for an elderly patient should be cautious, and lower [0m
[31mdoses may be sufficient in these patients [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: boxed_warning: WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS â€¢ Concomitant use of benzodiazepines and [0m
[31mopioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. [0m
[31mLimit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [0m[1;31m([0m[31msee WARNINGS and PRECAUTIONS [0m[1;31m)[0m[31m. â€¢ The use of benzodiazepines, [0m
[31mincluding lorazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other [0m
[31mmedications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. LORAZEPAM: boxed_warning: Before prescribing lorazepam and throughout [0m
[31mtreatment, assess each patientâ€™s risk for abuse, misuse, and addiction [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. â€¢ The continued use of benzodiazepines, including lorazepam, may lead to clinically significant physical [0m
[31mdependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of lorazepam after continued use may [0m
[31mprecipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam or reduce the dosage [0m[1;31m([0m[31m DOSAGE AND [0m
[31mADMINISTRATION and WARNINGS [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: precautions: Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lorazepam during pregnancy [0m[1;31m([0m[31msee PRECAUTIONS: Pregnancy[0m
[1;31m)[0m[31m. Nursing Instruct patients to notify their healthcare provider if they are breastfeeding or intend to breastfeed. Instruct breastfeeding patients using lorazepam to monitor infants for excessive [0m
[31msedation, poor feeding and poor weight gain, and to seek medical attention if they notice these signs [0m[1;31m([0m[31msee PRECAUTIONS: Nursing Mothers [0m[1;31m)[0m[31m. Essential Laboratory Tests Some patients on lorazepam have [0m
[31mdeveloped leukopenia, and some have had elevations of LDH. As with other benzodiazepines, periodic blood counts and liver function tests are recommended for patients on long-term therapy. Drug [0m
[31mInteractions The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. [0m
[31mBenzodiazepines interact at GABA A sites and opioids interact primarily at mu receptors. LORAZEPAM: precautions: When benzodiazepines and opioids are combined, the potential for benzodiazepines to [0m
[31msignificantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression [0m
[31mand sedation. The benzodiazepines, including lorazepam, produce increased CNS-depressant effects when administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, [0m
[31msedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. Concomitant use of clozapine and lorazepam may produce marked [0m
[31msedation, excessive salivation, hypotension, ataxia, delirium, and respiratory arrest. Concurrent administration of lorazepam with valproate results in increased plasma concentrations and reduced [0m
[31mclearance of lorazepam. LORAZEPAM: precautions: Lorazepam dosage should be reduced to approximately [0m[1;31m50[0m[31m% when coadministered with valproate. Concurrent administration of lorazepam with probenecid may [0m
[31mresult in a more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. Lorazepam dosage needs to be reduced by approximately [0m[1;31m50[0m[31m% when coadministered [0m
[31mwith probenecid. The effects of probenecid and valproate on lorazepam may be due to inhibition of glucuronidation. Administration of theophylline or aminophylline may reduce the sedative effects of [0m
[31mbenzodiazepines, including lorazepam. Carcinogenesis and Mutagenesis No evidence of carcinogenic potential emerged in rats during an [0m[1;31m18[0m[31m-month study with lorazepam. No studies regarding mutagenesis [0m
[31mhave been performed. LORAZEPAM: pregnancy: Pregnancy Pregnancy Exposure Registry There is a pregnancy registry that monitors pregnancy outcomes in women exposed to psychiatric medications, including [0m
[31mlorazepam, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at [0m[1;31m1[0m[31m-[0m[1;31m866[0m[31m-[0m[1;31m961[0m[31m-[0m[1;31m2388[0m[31m or visiting online at [0m
[4;31mhttps://womensmentalhealth.org/pregnancyregistry/.[0m[31m Risk Summary Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal [0m
[31mwithdrawal [0m[1;31m([0m[31msee WARNINGS: Neonatal Sedation and Withdrawal Syndrome and Clinical Considerations [0m[1;31m)[0m[31m. Available data from published observational studies of pregnant women exposed to benzodiazepines do [0m
[31mnot report a clear association with benzodiazepines and major birth defects [0m[1;31m([0m[31msee Data[0m[1;31m)[0m[31m . The background risk of major birth defects and miscarriage for the indicated population is unknown. All [0m
[31mpregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. LORAZEPAM: pregnancy: general population, the estimated risk of major birth defects and of miscarriage [0m
[31min clinically recognized pregnancies is [0m[1;31m2[0m[31m% to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m% to [0m[1;31m20[0m[31m%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Benzodiazepines cross the placenta and may produce respiratory [0m
[31mdepression, hypotonia and sedation in neonates. Monitor neonates exposed to lorazepam during pregnancy or labor for signs of sedation, respiratory depression, hypotonia, and feeding problems. Monitor [0m
[31mneonates exposed to lorazepam during pregnancy for signs of withdrawal. Manage these neonates accordingly [0m[1;31m([0m[31msee WARNINGS: Neonatal Sedation and Withdrawal Syndrome [0m[1;31m)[0m[31m. Data Human Data Published data [0m
[31mfrom observational studies on the use of benzodiazepines during pregnancy do not report a clear association with benzodiazepines and major birth defects.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: openfda: pharm_class_cs         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: drug_interactions: Drug Interactions The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites [0m
[31min the CNS that control respiration. Benzodiazepines interact at GABA A sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for [0m
[31mbenzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for [0m
[31mrespiratory depression and sedation. The benzodiazepines, including lorazepam, produce increased CNS-depressant effects when administered with other CNS depressants such as alcohol, barbiturates, [0m
[31mantipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. LORAZEPAM: drug_interactions: Concomitant use of [0m
[31mclozapine and lorazepam may produce marked sedation, excessive salivation, hypotension, ataxia, delirium, and respiratory arrest. Concurrent administration of lorazepam with valproate results in [0m
[31mincreased plasma concentrations and reduced clearance of lorazepam. Lorazepam dosage should be reduced to approximately [0m[1;31m50[0m[31m% when coadministered with valproate. Concurrent administration of lorazepam [0m
[31mwith probenecid may result in a more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. Lorazepam dosage needs to be reduced by approximately [0m[1;31m50[0m[31m% [0m
[31mwhen coadministered with probenecid. The effects of probenecid and valproate on lorazepam may be due to inhibition of glucuronidation. Administration of theophylline or aminophylline may reduce the [0m
[31msedative effects of benzodiazepines, including lorazepam.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: openfda: spl_id         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: clinical_pharmacology: CLINICAL PHARMACOLOGY Studies in healthy volunteers show that in single high doses lorazepam has a tranquilizing action on the central nervous system with no[0m
[31mappreciable effect on the respiratory or cardiovascular systems. Lorazepam is readily absorbed with an absolute bioavailability of [0m[1;31m90[0m[31m%. Peak concentrations in plasma occur approximately [0m[1;31m2[0m[31m hours [0m
[31mfollowing administration. The peak plasma level of lorazepam from a [0m[1;31m2[0m[31m mg dose is approximately [0m[1;31m20[0m[31m ng/mL. The mean half-life of unconjugated lorazepam in human plasma is about [0m[1;31m12[0m[31m hours and for its [0m
[31mmajor metabolite, lorazepam glucuronide, about [0m[1;31m18[0m[31m hours. At clinically relevant concentrations, lorazepam is approximately [0m[1;31m85[0m[31m% bound to plasma proteins. Lorazepam is rapidly conjugated at its [0m
[1;31m3[0m[31m-hydroxy group into lorazepam glucuronide which is then excreted in the urine. Lorazepam glucuronide has no demonstrable central nervous system [0m[1;31m([0m[31mCNS[0m[1;31m)[0m[31m activity in animals. LORAZEPAM: [0m
[31mclinical_pharmacology: The plasma levels of lorazepam are proportional to the dose given. There is no evidence of accumulation of lorazepam on administration up to [0m[1;31m6[0m[31m months. Studies comparing young [0m
[31mand elderly subjects have shown that advancing age does not have a significant effect on the pharmacokinetics of lorazepam. However, in one study involving single intravenous doses of [0m[1;31m1.5[0m[31m to [0m[1;31m3[0m[31m mg of [0m
[31mlorazepam Injection, mean total body clearance of lorazepam decreased by [0m[1;31m20[0m[31m% in [0m[1;31m15[0m[31m elderly subjects of [0m[1;31m60[0m[31m to [0m[1;31m84[0m[31m years of age compared to that in [0m[1;31m15[0m[31m younger subjects of [0m[1;31m19[0m[31m to [0m[1;31m38[0m[31m years of age.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: dosage_and_administration: DOSAGE AND ADMINISTRATION Lorazepam tablets are administered orally. For optimal results, dose, frequency of administration, and duration of therapy [0m
[31mshould be individualized according to patient response. To facilitate this, [0m[1;31m0.5[0m[31m mg, [0m[1;31m1[0m[31m mg, and [0m[1;31m2[0m[31m mg tablets are available. The usual range is [0m[1;31m2[0m[31m to [0m[1;31m6[0m[31m mg/day given in divided doses, the largest dose [0m
[31mbeing taken before bedtime, but the daily dosage may vary from [0m[1;31m1[0m[31m to [0m[1;31m10[0m[31m mg/day. For anxiety, most patients require an initial dose of [0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m mg/day given two times a day or three times a day. For [0m
[31minsomnia due to anxiety or transient situational stress, a single daily dose of [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m mg may be given, usually at bedtime. For elderly or debilitated patients, an initial dosage of [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m mg/day in [0m
[31mdivided doses is recommended, to be adjusted as needed and tolerated. LORAZEPAM: dosage_and_administration: The dosage of lorazepam tablets should be increased gradually when needed to help avoid [0m
[31madverse effects. When higher dosage is indicated, the evening dose should be increased before the daytime doses. Discontinuation or Dosage Reduction of Lorazepam Tablets To reduce the risk of [0m
[31mwithdrawal reactions, use a gradual taper to discontinue lorazepam tablets or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the [0m
[31mprevious tapered dosage level. Subsequently decrease the dosage more slowly [0m[1;31m([0m[31msee WARNINGS: Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE: Dependence [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:LORAZEPAM label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of aplastic anemia. The adverse reactions section lists various potential [0m
[32mside effects, including hematologic issues such as thrombocytopenia, agranulocytosis, and pancytopenia, but aplastic anemia is not specifically mentioned.[0m

[32mSOURCE: LORAZEPAM label[0m
[32mEXTRACT_START_END: [0m[32m...[0m[32mthrombocytopenia, agranulocytosis, pancytopenia; hypothermia; and autonomic manifestations[0m[32m...[0m
*[1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The available information from the LORAZEPAM label does not [0m
[34mindicate that lorazepam increases or decreases the risk of aplastic anemia. The adverse reactions section lists various potential side effects, including hematologic issues such as thrombocytopenia, [0m
[34magranulocytosis, and pancytopenia, but aplastic anemia is not specifically mentioned.[0m

[34mSOURCE: LORAZEPAM label[0m
[34mEXTRACT_START_END: [0m[34m...[0m[34mthrombocytopenia, agranulocytosis, pancytopenia; hypothermia; and autonomic manifestations[0m[34m...[0m
 [1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does LORAZEPAM increase or decrease the risk of aplastic anemia?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether LORAZEPAM increases or decreases the risk of aplastic anemia."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of aplastic anemia. The adverse reactions section [0m
[32mlists various potential side effects, including hematologic issues such as thrombocytopenia, agranulocytosis, and pancytopenia, but aplastic anemia is not specifically mentioned."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of aplastic anemia. Aplastic anemia is not specifically mentioned as [0m
[32ma side effect in the label."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does LORAZEPAM increase or decrease the risk of aplastic anemia?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether LORAZEPAM increases or decreases the risk of aplastic anemia."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of aplastic anemia. The adverse reactions section [0m
[34mlists various potential side effects, including hematologic issues such as thrombocytopenia, agranulocytosis, and pancytopenia, but aplastic anemia is not specifically mentioned."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of aplastic anemia. Aplastic anemia is not specifically mentioned as [0m
[34ma side effect in the label."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does LORAZEPAM increase or decrease the risk of aplastic anemia?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether LORAZEPAM increases or decreases the risk of aplastic anemia.[0m
[1;31m2[0m[31m. FDAHandler responded that the available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of aplastic anemia. The adverse reactions section lists[0m
[31mvarious potential side effects, including hematologic issues such as thrombocytopenia, agranulocytosis, and pancytopenia, but aplastic anemia is not specifically mentioned.[0m
[31m        -----[0m
[31m        Final answer: The available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of aplastic anemia. Aplastic anemia is not specifically [0m
[31mmentioned as a side effect in the label.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-aplastic anemia-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of aplastic anemia. Aplastic anemia is not specifically mentioned as a side effect [0m
[32min the label.[0m
